RU2001126525A - The use of xenon for the treatment of neurointoxications - Google Patents

The use of xenon for the treatment of neurointoxications

Info

Publication number
RU2001126525A
RU2001126525A RU2001126525/14A RU2001126525A RU2001126525A RU 2001126525 A RU2001126525 A RU 2001126525A RU 2001126525/14 A RU2001126525/14 A RU 2001126525/14A RU 2001126525 A RU2001126525 A RU 2001126525A RU 2001126525 A RU2001126525 A RU 2001126525A
Authority
RU
Russia
Prior art keywords
xenon
use according
neurointoxication
composition
caused
Prior art date
Application number
RU2001126525/14A
Other languages
Russian (ru)
Other versions
RU2246949C2 (en
Inventor
Кристиан ПЕТЦЕЛЬТ
Вольфганг Й. КОКС
Original Assignee
Ага Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19910986A external-priority patent/DE19910986C2/en
Application filed by Ага Аб filed Critical Ага Аб
Publication of RU2001126525A publication Critical patent/RU2001126525A/en
Application granted granted Critical
Publication of RU2246949C2 publication Critical patent/RU2246949C2/en

Links

Claims (19)

1. Применение ксенона или газовых смесей, содержащих ксенон, для лечения нейроинтоксикаций.1. The use of xenon or gas mixtures containing xenon for the treatment of neurointoxications. 2. Применение по п.1, отличающееся тем, что нейроинтоксикация вызывается избытком нейромедиаторов.2. The use according to claim 1, characterized in that the neurointoxication is caused by an excess of neurotransmitters. 3. Применение по п.1 или 2, отличающееся тем, что ксенон уменьшает высвобождение допамина, глутамата и/или норадреналина.3. The use according to claim 1 or 2, characterized in that xenon reduces the release of dopamine, glutamate and / or norepinephrine. 4. Применение по любому из пп.1-3, отличающееся тем, что нейроинтоксикация вызывается апоплексией.4. The use according to any one of claims 1 to 3, characterized in that the neurointoxication is caused by apoplexy. 5. Применение по любому из пп.1-3, отличающееся тем, что нейроинтоксикация вызывается злоупотреблением лекарственными средствами.5. The use according to any one of claims 1 to 3, characterized in that the neurointoxication is caused by drug abuse. 6. Применение по любому из пп.1-3, отличающееся тем, что нейроинтоксикация вызывается дефицитом кислорода при рождении.6. The use according to any one of claims 1 to 3, characterized in that the neurointoxication is caused by oxygen deficiency at birth. 7. Применение по любому из пп.1-3, отличающееся тем, что нейроинтоксикация связана с болезнью Паркинсона, шизофренией или синдромом Жиль де ла Туретта.7. The use according to any one of claims 1 to 3, characterized in that neurointoxication is associated with Parkinson's disease, schizophrenia or Gilles de la Tourette’s syndrome. 8. Применение по любому из пп.1-3, отличающееся тем, что нейроинтоксикация вызывается черепномозговой травмой.8. The use according to any one of claims 1 to 3, characterized in that the neurointoxication is caused by a traumatic brain injury. 9. Применение по любому из пп.1-3, отличающееся тем, что ксенон или газообразная смесь, содержащая ксенон, используются в аппарате искусственного кровообращения.9. The use according to any one of claims 1 to 3, characterized in that xenon or a gaseous mixture containing xenon are used in a cardiopulmonary bypass. 10. Применение по любому из пп.1-3, отличающееся тем, что нейроинтоксикация вызывает потерю слуха.10. The use according to any one of claims 1 to 3, characterized in that neurointoxication causes hearing loss. 11. Применение по любому из пп.1-3, отличающееся тем, что нейроинтоксикация вызывается мигренью.11. The use according to any one of claims 1 to 3, characterized in that the neurointoxication is caused by migraine. 12. Применение по любому из пп.1-10, отличающееся тем, что вводимая для осуществления терапевтического лечения композиция содержит 5-90 об.% ксенона.12. The use according to any one of claims 1 to 10, characterized in that the composition introduced for the implementation of therapeutic treatment contains 5-90 vol.% Xenon. 13. Применение по п.12, отличающееся тем, что композиция содержит 5-30 об.% ксенона.13. The use according to claim 12, characterized in that the composition contains 5-30 vol.% Xenon. 14. Применение по любому из пп.1-13, отличающееся тем, что вводимая для осуществления терапевтического лечения композиция дополнительно содержит кислород и/или азот и/или воздух.14. The use according to any one of claims 1 to 13, characterized in that the composition introduced for the implementation of therapeutic treatment further comprises oxygen and / or nitrogen and / or air. 15. Применение по п.12, отличающееся тем, что соотношение ксенона и кислорода в композиции составляет 80-20 об.%.15. The application of item 12, wherein the ratio of xenon and oxygen in the composition is 80-20 vol.%. 16. Композиция, включающая ксенон или газообразную смесь, содержащую ксенон, предназначенная для лечения нейроинтоксикаций.16. A composition comprising xenon or a gaseous mixture containing xenon, intended for the treatment of neurointoxications. 17. Композиция по п.13, включающая ксенон или газообразную смесь, содержащую кислород.17. The composition according to item 13, comprising xenon or a gaseous mixture containing oxygen. 18. Способ получения композиции, предназначенной для ингаляции, предусматривающий смешение ксенона с другим безвредным для человека газом.18. A method of obtaining a composition intended for inhalation, comprising mixing xenon with another gas that is harmless to humans. 19. Способ по п.18, где ксенон смешивают с газом, содержащим кислород.19. The method according to p, where xenon is mixed with a gas containing oxygen.
RU2001126525/14A 1999-03-11 2000-03-08 Method for applying xenon for treating neurointoxication RU2246949C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19910986.9 1999-03-11
DE19910986A DE19910986C2 (en) 1999-03-11 1999-03-11 Use of xenon in the treatment of neurointoxication

Publications (2)

Publication Number Publication Date
RU2001126525A true RU2001126525A (en) 2003-06-27
RU2246949C2 RU2246949C2 (en) 2005-02-27

Family

ID=7900688

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001126525/14A RU2246949C2 (en) 1999-03-11 2000-03-08 Method for applying xenon for treating neurointoxication

Country Status (29)

Country Link
US (3) US6559190B1 (en)
EP (1) EP1158992B2 (en)
JP (1) JP4954373B2 (en)
KR (1) KR100674407B1 (en)
CN (1) CN1170544C (en)
AR (1) AR022886A1 (en)
AT (1) ATE248599T1 (en)
AU (1) AU757361B2 (en)
BG (1) BG105889A (en)
BR (1) BR0010456A (en)
CA (1) CA2367136C (en)
CZ (1) CZ302864B6 (en)
DE (2) DE19910986C2 (en)
DK (1) DK1158992T3 (en)
EE (1) EE200100480A (en)
ES (1) ES2206202T5 (en)
HK (1) HK1048073B (en)
HU (1) HUP0201393A3 (en)
IL (2) IL145177A0 (en)
MD (1) MD2935C2 (en)
NO (1) NO20014379L (en)
PL (1) PL202941B1 (en)
PT (1) PT1158992E (en)
RS (1) RS49756B (en)
RU (1) RU2246949C2 (en)
SI (1) SI1158992T1 (en)
SK (1) SK285111B6 (en)
WO (1) WO2000053192A1 (en)
ZA (1) ZA200107291B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011081612A1 (en) * 2009-12-31 2011-07-07 Bondarenko Vitaliy Leonidovich Use of krypton or xenon as an antiviral agent

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
DE10045829A1 (en) * 2000-09-14 2002-04-04 Messer Griesheim Gmbh Volatile anesthetic with xenon
DE10054563A1 (en) * 2000-11-03 2002-05-16 Messer Griesheim Gmbh Method and device for making concrete
WO2002045583A1 (en) * 2000-12-07 2002-06-13 Mclean Hospital Corporation Use of magnetic resonance imaging in diagnosis of membrane fluidity-related disorders
GB0210021D0 (en) 2002-05-01 2002-06-12 Air Prod & Chem Ultrasonic gas analyser
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
JP2005533062A (en) * 2002-06-12 2005-11-04 メツサー グリースハイム ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Brain protection with xenon-containing gas
AU2003249959A1 (en) * 2002-07-05 2004-01-23 Messer Griesheim Gmbh Adjuvant containing xenon
GB0218153D0 (en) * 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
US7337776B2 (en) 2002-08-20 2008-03-04 Aga Ab Methods for easing pain and anxiety from atrial or ventricular defibrillation
US7681572B2 (en) 2002-08-20 2010-03-23 Aga Ab Method and devices for administration of therapeutic gases
FR2858233B1 (en) * 2003-07-30 2008-04-11 Air Liquide Sante Int INHALABLE GAS MEDICINE BASED ON XENON AND NITROGEN PROTOXIDE
EP1670489B1 (en) 2003-10-10 2007-12-12 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
AU2004283448B2 (en) * 2003-10-21 2009-02-19 Imperial Innovations Limited Use of xenon for the prevention of programmed cell death
FR2863169B1 (en) * 2003-12-08 2006-02-10 Air Liquide Sante Int ARGON-BASED INHALABLE GAS MEDICINE FOR THE TREATMENT OF NEURO-INTOXICATIONS
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
US7070005B2 (en) * 2004-02-10 2006-07-04 Planetair Turf Products, Llc Soil aerator assembly
ATE553757T1 (en) * 2004-08-02 2012-05-15 John W Olney PREVENTION OF PATHOLOGICAL INCREASE IN NERVOUS CELL SUICIDE RATES IN IMMATURE NERVOUS SYSTEMS
WO2007075100A1 (en) * 2005-12-27 2007-07-05 Zakrytoe Aktsionernoe Obshchestvo 'atom-Med Center' Method for treating drug dependence
EP1980260A1 (en) * 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
US8435569B2 (en) 2007-04-30 2013-05-07 Nnoxe Pharmaceutiques Inc. Pharmaceutical composition comprising at least one thrombolytic agent (A) and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (en) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa USE OF XENON FOR THE PROTECTION OF DAMAGED DAMAGE ORGANS
WO2010035074A1 (en) * 2008-09-25 2010-04-01 Nnoxe Pharmaceutiques Inc Use of nitrous oxide, argon, xenon, helium, or neon, for the manufacture of a pharmaceutical composition for treating ischemic insults in patients who cannot be treated with thrombolytic agents
FR2952305B1 (en) * 2009-11-10 2012-04-27 Air Liquide XENON-BASED INHALABLE MEDICINE FOR TREATING OR PREVENTING DYSKINESIES
FR2956323B1 (en) 2010-02-15 2013-12-20 Air Liquide ARGON-BASED INHALABLE GAS MEDICINE AGAINST PERIPHERAL ORGAN DEFECTS OR MALFUNCTIONS
FR2960779A1 (en) 2010-06-08 2011-12-09 Air Liquide INHALABLE GASEOUS MEDICINE BASED ON KRYPTON AGAINST PERIPHERAL ORGAN DEFECTS OR FAILURES
FR2964036B1 (en) 2010-08-24 2013-04-12 Air Liquide INHALABLE GASEOUS MEDICINE BASED ON KRYPTON FOR THE TREATMENT OF NEURO-INTOXICATIONS
WO2012109107A1 (en) 2011-02-07 2012-08-16 Rich Products Corporation Method for preserving cells and cell cultures
FR2975597B1 (en) * 2011-05-24 2013-12-27 Air Liquide USE OF NEON FOR THE TREATMENT OF NEURO-INTOXICATIONS, IN PARTICULAR ENURODEGENERATIVE AND DEMYELINISANT DISEASES
AR088166A1 (en) 2011-09-26 2014-05-14 Rich Products Corp METHOD FOR THE PRESERVATION OF LIVE FABRIC
RU2489154C1 (en) * 2012-05-31 2013-08-10 Сергей Александрович Наумов Method of treating viral hepatites
CN110464709A (en) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 For treating the neuroprotective liposome composition and method of apoplexy
FR2996459B1 (en) * 2012-10-09 2015-02-06 Air Liquide USE OF AN ARGON / XENON MIXTURE TO PREVENT OR TREAT THE NEUROLOGICAL CONSEQUENCES OF A SEPTIC SHOCK
FR2996458B1 (en) 2012-10-09 2015-02-27 Air Liquide USE OF XENON TO PREVENT OR TREAT THE NEUROLOGICAL CONSEQUENCES OF A SEPTIC SHOCK
FR2996457B1 (en) 2012-10-09 2019-11-29 L'air Liquide,Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude USE OF ARGON TO PREVENT OR TREAT THE NEUROLOGICAL CONSEQUENCES OF A SEPTIC SHOCK
WO2014093277A1 (en) 2012-12-11 2014-06-19 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
EP2968126B1 (en) 2013-03-15 2022-04-06 The Board of Regents of The University of Texas System Liquids rich in noble gas and methods of their preparation and use
FR3007983B1 (en) * 2013-07-08 2015-06-26 Air Liquide ASSOCIATION OF XENON AND AN NMDA RECEPTOR ANTAGONIST TO FIGHT NEURODEGENERATIVE DISEASE
FR3022456B1 (en) * 2014-06-20 2016-07-15 Air Liquide XENON ASSOCIATED WITH ANTAGONIST OF NMDA RECEPTORS TO FIGHT TUMOR PROLIFERATION IN THE CENTRAL NERVOUS SYSTEM
FR3027226B1 (en) * 2014-10-17 2017-12-08 L'air Liquide Sa Pour L'etude Et L'exploitation Des Procedes Georges Claude MEDICAMENT FOR TREATING A DISEASE RELATED TO A DYSFUNCTION OF THE DOPAMINERGIC SYNAPTIC TRANSMISSION
AU2016281656B2 (en) * 2015-06-23 2019-05-30 Nobilis Therapeutics, Inc. Therapeutic immune modulation using noble gas compositions
EP3373940A4 (en) * 2015-11-09 2019-10-02 The McLean Hospital Corporation Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
US20170341980A1 (en) * 2016-05-31 2017-11-30 Noblis Therapeutics, Inc. Noble gas neuroprotection and neuroregeneration from treatment related neurotoxicity
US10485825B2 (en) * 2016-08-29 2019-11-26 Nobilis Therapeutics, Inc. Prevention of pregnancy complications by noble gas administration
US20200054671A1 (en) * 2016-10-31 2020-02-20 Nobilis Therapeutics, Inc. Treatment of anxiety disorder and augmentation of anti-anxiety interventions by administration of noble gas containing mixtures
CN107569509B (en) * 2017-02-22 2018-09-21 滨州医学院 The purposes of xenon or xenon-133 gas mixture in the preparation for preparing treatment epilepsy
CN108986622A (en) * 2018-08-16 2018-12-11 广州迈普再生医学科技股份有限公司 A kind of intracranial hematoma microtrauma puncture removes art training device and preparation method thereof
RU2712804C1 (en) * 2018-08-29 2020-01-31 Жовнерчук Инна Юрьевна Method for correction of human functional state in confined space

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
US5228434A (en) * 1991-07-16 1993-07-20 Praxair Technology, Inc. Mixture for anesthesia
US5357959A (en) * 1993-04-16 1994-10-25 Praxair Technology, Inc. Altered dipole moment magnetic resonance imaging method
US5846556A (en) * 1996-06-14 1998-12-08 Brooks; Bradley S. Inhalant for reducing stress and method of use
IT1286058B1 (en) * 1996-10-29 1998-07-07 Siad Societa Italiana Acetilen PROCEDURE AND EQUIPMENT FOR THE PURIFICATION AND RECOVERY OF XENON AND OTHER NOBLE GASES IN ANESTHETICS SYSTEMS
DE19709704C2 (en) * 1997-03-10 1999-11-04 Michael Georgieff Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia
DE19823606C2 (en) * 1998-05-27 2002-02-28 Draeger Medical Ag Use of perfluorocarbons in a breathing gas mixture as well as the device
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011081612A1 (en) * 2009-12-31 2011-07-07 Bondarenko Vitaliy Leonidovich Use of krypton or xenon as an antiviral agent

Similar Documents

Publication Publication Date Title
RU2001126525A (en) The use of xenon for the treatment of neurointoxications
JP2002538209A5 (en)
CA2367136A1 (en) Use of xenon for treating neurointoxications
ATE439829T1 (en) GEL OR SOLUTION CONTAINING DIHYDROTESTOSTERONE, PROCESS OF PRODUCTION AND USE THEREOF
PT1263725E (en) NEW COMPOUNDS
JP2004510493A5 (en)
EP1610751A4 (en) Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
ATE482747T1 (en) NEW AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USES
IL132156A0 (en) Neoglycoproteins
IL203923A (en) Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
MX9701292A (en) Spiro-azabicyclic compounds useful in therapy.
DE60219954D1 (en) New indole-2-one derivatives
DE602005016601D1 (en) 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND APPLICATION METHODS
ATE409185T1 (en) QUINAZOLINE DERIVATIVES
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
ATE380016T1 (en) SPREADING PROCESS FOR PRODUCING POWDER FORMULATIONS
CR7271A (en) NEW MELATONIN-BASED PHARMACEUTICAL FORMULATIONS AND SIMILAR COMPOUNDS FOR USE IN SOUND DISORDERS
TR199900087T2 (en) Alfo-amino acid amides, their preparation and therapeutic uses.
RU2000119148A (en) PHARMACEUTICAL COMPOSITIONS
IL168307A (en) Compositions containing roflumilast and (r,r)-formoterol
NO20024673D0 (en) Controlled-release pharmaceutical composition for oral use containing midodrine and / or desglymidodrine
SE9804126D0 (en) New pharmaceutical composition
ATE416162T1 (en) NAPHTHAMIDE DERIVATIVES AND USE THEREOF
DE3671746D1 (en) SULFINYL- AND SULFONYL-SUBSTITUTED 3-BENZAZEPINE.
RU2000116316A (en) MEANS FOR TREATING BURNS RAS